Search

Displaying results 5611 - 5620 of 5876 in total
  1. Drug

    Heptabarbital

    go.drugbank.com/drugs/DB01354
    Experimental

    Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.

  2. Drug

    TJ003234

    go.drugbank.com/drugs/DB16470
    Investigational

  3. Drug

    Lemuteporfin

    go.drugbank.com/drugs/DB04980
    Investigational

    Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

  4. Drug

    Butyrylcholinesterase

    go.drugbank.com/drugs/DB06352
    Investigational

  5. Drug

    Tagetitoxin

    go.drugbank.com/drugs/DB04788
    Experimental

    Tagetitoxin is a bacterial phytotoxin. It preferentially inhibits eukaryotic RNA polymerase.

  6. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.

  7. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

  8. Drug

    Josamycin

    go.drugbank.com/drugs/DB01321
    Investigational

    A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.

  9. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

  10. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and ...